Literature DB >> 22562027

Cytogenetic and FMS-like tyrosine kinase 3 mutation analyses in acute promyelocytic leukemia patients.

Marjan Yaghmaie1,2, Kamran Alimoghaddam2, Hossein Mozdarani1, Ardeshir Ghavamzadeh2, Marjan Hajhashemi2, Mozaffar Aznab3, Seyed H Ghaffari2.   

Abstract

BACKGROUND: The secondary genetic changes other than the promyelocytic leukemia-retinoic acid receptor (PML-RARA) fusion gene may contribute to the acute promyelocytic leukemogenesis. Chromosomal alterations and mutation of FLT3 (FMS-like tyrosine kinase 3) tyrosine kinase receptor are the frequent genetic alterations in acute myeloid leukemia. However, the prognostic significance of FLT3 mutations in acute promyelocytic leukemia (APL) is not firmly established.
METHODS: In this study, the chromosomal abnormalities were analyzed by bone marrow cytogenetic in 45 APL patients and FLT3 internal tandem duplications (ITD) screening by fragment length analysis and FLT3 D835 mutation by melting curve analysis were screened in 23 APL samples.
RESULTS: Cytogenetic study showed 14.3% trisomy 8 and 17.1% chromosomal abnormalities other than t(15;17). About 13% of the patients had FLT3 ITD, and 26% had D835 point mutation. FLT3 ITD mutation was associated with higher white blood cell count at presentation and poor prognosis.
CONCLUSION: The PML-RARA translocation alone may not be sufficient to induce leukemia. Therefore, we assume that FLT3 mutations and the other genetic and chromosomal alterations may cooperate with PML-RARA in the development of APL disease.

Entities:  

Keywords:  Chromosome aberrations; FMS-like tyrosine kinase 3; Acute promyelocytic leukemia

Mesh:

Substances:

Year:  2012        PMID: 22562027      PMCID: PMC3614257          DOI: 10.6091/ibj.961.2012

Source DB:  PubMed          Journal:  Iran Biomed J        ISSN: 1028-852X


  30 in total

Review 1.  Flt3 mutations and leukaemia.

Authors:  Panagiotis D Kottaridis; Rosemary E Gale; David C Linch
Journal:  Br J Haematol       Date:  2003-08       Impact factor: 6.998

2.  A FLT3-targeted tyrosine kinase inhibitor is cytotoxic to leukemia cells in vitro and in vivo.

Authors:  Mark Levis; Jeffrey Allebach; Kam-Fai Tse; Rui Zheng; Brenda R Baldwin; B Douglas Smith; Susan Jones-Bolin; Bruce Ruggeri; Craig Dionne; Donald Small
Journal:  Blood       Date:  2002-06-01       Impact factor: 22.113

3.  Internal tandem duplication and Asp835 mutations of the FMS-like tyrosine kinase 3 (FLT3) gene in acute promyelocytic leukemia.

Authors:  Lee-Yung Shih; Ming-Chung Kuo; Der-Cherng Liang; Chein-Fuang Huang; Tung-Liang Lin; Jin-Hou Wu; Po-Nan Wang; Po Dunn; Chang-Liang Lai
Journal:  Cancer       Date:  2003-09-15       Impact factor: 6.860

Review 4.  FLT3: ITDoes matter in leukemia.

Authors:  M Levis; D Small
Journal:  Leukemia       Date:  2003-09       Impact factor: 11.528

5.  FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact.

Authors:  Wing Y Au; Alvin Fung; Chor S Chim; Albert K Lie; Raymond Liang; Edmond S K Ma; Cheuk H Chan; Kit F Wong; Yok L Kwong
Journal:  Br J Haematol       Date:  2004-05       Impact factor: 6.998

6.  Analysis of FLT3 length mutations in 1003 patients with acute myeloid leukemia: correlation to cytogenetics, FAB subtype, and prognosis in the AMLCG study and usefulness as a marker for the detection of minimal residual disease.

Authors:  Susanne Schnittger; Claudia Schoch; Martin Dugas; Wolfgang Kern; Peter Staib; Christian Wuchter; Helmut Löffler; Cristina Maria Sauerland; Hubert Serve; Thomas Büchner; Torsten Haferlach; Wolfgang Hiddemann
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

7.  Targeted inhibition of FLT3 overcomes the block to myeloid differentiation in 32Dcl3 cells caused by expression of FLT3/ITD mutations.

Authors:  Rui Zheng; Alan D Friedman; Donald Small
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

8.  Alterations of the FLT3 gene in acute promyelocytic leukemia: association with diagnostic characteristics and analysis of clinical outcome in patients treated with the Italian AIDA protocol.

Authors:  N I Noguera; M Breccia; M Divona; D Diverio; V Costa; S De Santis; G Avvisati; M B Pinazzi; M C Petti; F Mandelli; F Lo Coco
Journal:  Leukemia       Date:  2002-11       Impact factor: 11.528

Review 9.  The role of FLT3 in haematopoietic malignancies.

Authors:  Derek L Stirewalt; Jerald P Radich
Journal:  Nat Rev Cancer       Date:  2003-09       Impact factor: 60.716

10.  FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor.

Authors:  M Carmen Chillón; Carina Fernández; Ramón García-Sanz; Ana Balanzategui; Fernando Ramos; Javier Fernández-Calvo; Marcos González; Jesús F San Miguel
Journal:  Hematol J       Date:  2004
View more
  2 in total

1.  FMS-related tyrosine kinase 3 internal tandem duplication (FLT3-ITD): a villain among others.

Authors:  Vanessa Y N de Arruda; Lisa N Matsuzaki; Maria de Lourdes Chauffaille
Journal:  Rev Bras Hematol Hemoter       Date:  2017-04-03

Review 2.  The Impact of Flt3 Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis.

Authors:  Gledson L Picharski; Diancarlos P Andrade; Ana Luiza M R Fabro; Luana Lenzi; Fernanda S Tonin; Raul C Ribeiro; Bonald C Figueiredo
Journal:  Cancers (Basel)       Date:  2019-09-05       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.